Evgen Pharma (GB:TCF) has released an update.
TheraCryf plc, previously known as Evgen Pharma, has reported significant progress in its drug development endeavors, particularly with SFX-01, their lead clinical compound for various cancers including glioblastoma. The company has successfully extended its cash runway, secured a grant for a GBM clinical trial, and observed promising results from pre-clinical studies. Additionally, TheraCryf’s acquisition of Chronos Therapeutics has expanded its neuropsychiatry portfolio, with the integration of both companies proceeding smoothly.
For further insights into GB:TCF stock, check out TipRanks’ Stock Analysis page.
